Cellulose Sulfate (CS) Gel and HIV in Nigeria

Phase 3TerminatedNCT00120770

FHI 3602,160 enrolled

Overview

This is a Phase 3, multi-center, randomized, placebo-controlled trial to determine the effectiveness and safety of the 6% cellulose sulfate (CS) vaginal gel for the prevention of HIV infection.

This is a Phase 3, multi-center, randomized, placebo-controlled trial to assess the effectiveness of CS gel in preventing male-to-female vaginal transmission of HIV among HIV sero-negative women at high risk for HIV infection. Eligible participants who are HIV negative, at risk for becoming infected, and are willing to use a vaginal microbicide each time they have intercourse throughout 12 months of study participation will be recruited in Port Harcourt and Lagos, Nigeria. The enrollment phase will last until 2,160 women have enrolled. It is anticipated that the enrollment will be completed within 12 months.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

2,160

Conditions

HIV Infections Gonorrhea Chlamydia Infections

Interventions

Cellulose Sulfate Vaginal Gel (Microbicide)DRUG

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 35 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Willing and able to give informed consent * At least 18 years old and not more than 35 years old * Average of three vaginal coital acts per week with a male partner * More than one male sexual partner in the last 3 months * Willing to use study product as directed * Willing to adhere to follow-up schedule * Willing to participate in the study for 12 months * Willing to report self-medication during study participation * Willing to give urine for pregnancy testing; self-administered vaginal swabs for GC/CT testing; OMT for HIV monthly; finger prick for HIV confirmation if required; and blood draw for syphilis and HIV at baseline, and for HIV at the final visit * Willing to not use a spermicide, other vaginal contraceptive, or vaginal lubricant during the study * At least 3 months since end of the last pregnancy Exclusion Criteria: * History of adverse reactions to the study products, including latex * Pregnant or desire a pregnancy during the 12 months of participation * Injection drug user * Gynecological abnormality that may have an impact on the safety and/or response to the study gel according to the investigator * HIV positive as diagnosed by OraQuick® rapid test * Participation in any other microbicide research * Discontinued from the CS study previously * Any condition (social or medical) which, in the opinion of the investigator, would make study participation unsafe or complicate data interpretation

Locations (2)

Lagos University, College of Medicine, Center 10151

Lagos, Nigeria

University of Port Harcourt Teaching Hospital, Center 10152

Port Harcourt, Nigeria

Outcomes

Primary Outcomes

Incidence of HIV-1 and HIV-2 infection as determined by detection of HIV antibodies from oral mucosal transudate (OMT) specimens.

Secondary Outcomes

Incidence of genital gonorrhea or chlamydia as determined by DNA probe technology from self-administered vaginal swabs.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.